Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Phase 2 Terminated 28 enrolled Stealth BioTherapeutics Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial

Timeline

Start: 2016-12
Primary completion: 2020-03-09
Completion: 2020-04-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elamipretide	Peptide	40 mg	Subcutaneous

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Summary

Timeline

Drugs

Indications